Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs

Drug Discovery Today

Volumn 21, Issue 5, 2016, Pages 712-717

  Whitty, Adrian ^a   Zhong, Mengqi ^a   Viarengo, Lauren ^a   Beglov, Dmitri ^b   Hall, David R ^c   Vajda, Sandor ^a,b  

^a USA   (United States)

^b BOSTON UNIVERSITY   (United States)

^c Acpharis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CLARITHROMYCIN; CYCLOSPORIN A; MACROCYCLIC COMPOUND; NAVITOCLAX; PACLITAXEL; RAPAMYCIN; RIFAMPICIN; ROXITHROMYCIN;

CONFORMATION; DRUG SOLUBILITY; DRUG STRUCTURE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; QUANTITATIVE ANALYSIS; REVIEW; CHEMISTRY; DRUG DESIGN; HUMAN; MOLECULAR MODEL;

DRUG DESIGN; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; MOLECULAR WEIGHT;

EID: 84975740643     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.02.005     Document Type: Short Survey

References (28)

1. A. Ganesan The impact of natural products upon modern drug discovery Curr. Opin. Chem. Biol. 12 2008 306 317
2. B.C. Doak, and et al. Oral druggable space beyond the Rule of 5: insights from drugs and clinical candidates Chem. Biol. 21 2014 1115 1142
3. E.M. Driggers, and et al. The exploration of macrocycles for drug discovery - an underexploited structural class Nat. Rev. Drug Discov. 7 2008 608 624
4. E.A. Villar, and et al. How proteins bind macrocycles Nat. Chem. Biol. 10 2014 723 731
5. F. Giordanetto, and J. Kihlberg Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57 2014 278 295
6. T. Rezai, and et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides J. Am. Chem. Soc. 128 2006 14073 14080
7. A.T. Bockus, and et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products J. Med. Chem. 58 2015 4581 4589
8. W.M. Hewitt, and et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products J. Am. Chem. Soc. 137 2015 715 721
9. A.T. Bockus, and et al. Form and function in cyclic peptide natural products: a pharmacokinetic perspective Curr. Top. Med. Chem. 13 2013 821 836
10. A.C. Rand, and et al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance MedChemComm 3 2012 1282 1289
11. J.B. Escalera, and et al. Predicting the solubility of drugs in solvent mixtures: multiple solubility maxima and the chameleonic effect J. Pharm. Pharmacol. 46 1994 172 176
12. G. Vistoli, and et al. Assessing drug-likeness: what are we missing? Drug Discov. Today 13 2008 285 294
13. G.L. Amidon, and et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in-vitro drug product dissolution and in-vivo bioavailability Pharm. Res. 12 1995 413 420
14. C.A. Lipinski, and et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
15. D.F. Veber, and et al. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
16. P. Ertl, and et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 43 2000 3714 3717
17. M. Vieth, and et al. Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 47 2004 224 232
18. J. Wang, and T. Hou Recent advances on aqueous solubility prediction Comb. Chem. High Throughput Screen. 14 2011 328 338
19. Y.A. Abramov Major source of error in QSPR prediction of intrinsic thermodynamic solubility of drugs: solid vs nonsolid state contributions? Mol. Pharm. 12 2015 2126 2141
20. M. Salahinejad, and et al. Aqueous solubility prediction: do crystal lattice interactions help? Mol. Pharm. 10 2013 2757 2766
21. F. Chevillard, and et al. In silico prediction of aqueous solubility: a multimodel protocol based on chemical similarity Mol. Pharm. 9 2012 3127 3135
22. C.R.W. Guimaraes, and et al. Use of 3D properties to characterize beyond Rule-of-5 property space for passive permeation J. Chem. Inf. Model. 52 2012 882 890
23. J.I. Levin Macrocycles in Drug Discovery 2014 Royal Society of Chemistry
24. N. El Tayar, and et al. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations J. Med. Chem. 36 1993 3757 3764
25. T. Oltersdorf, and et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
26. C. Tse, and et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
27. A.W. Roberts, and et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies Br. J. Haematol. 170 2015 669 678
28. T.J. Kipps, and et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia Leuk. Lymphoma 56 2015 2826 2833